Protein Summary
Common junctional plaque protein. The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton (By similarity). This gene encodes a major cytoplasmic protein which is the only known constituent common to submembranous plaques of both desmosomes and intermediate junctions. This protein forms distinct complexes with cadherins and desmosomal cadherins and is a member of the catenin family since it contains a distinct repeating amino acid motif cal ...more
- ENST00000310706
- ENSP00000311113
- ENSG00000173801
- ENST00000393930
- ENSP00000377507
- ENST00000393931
- ENSP00000377508
- CTNNG
- DP3
- DP3
- PDGB
- PKGB
- CTNNG
- DPIII
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
interacting protein | 0.99 | ||
biological process | 0.97 | ||
molecular function | 0.91 | ||
transcription factor binding site profile | 0.9 | ||
ligand (protein) perturbation | 0.83 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 123.19 (req: < 5)
Gene RIFs: 93 (req: <= 3)
Antibodies: 1171 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 123.19 (req: >= 5)
Gene RIFs: 93 (req: > 3)
Antibodies: 1171 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 35
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0